Connect with us


Germany Decided to Legalize, But When?



The new cool thing in Europe seems to be talking about impending cannabis legalizations for recreational use, which are not backed by anything other than a promise, and with no upcoming date. Germany just joined Switzerland and Luxembourg in claiming it made the decision to legalize recreational cannabis, but apparently we’ll have to wait a little longer to find out when.

Germany stated its set to legalize cannabis, but what backs this up, and when will it happen? This publication focuses on cannabis and psychedelics stories, bringing you everything going on in these changing landscapes today. Follow along by subscribing to the THC Weekly Newsletter, and also get first-place access to deals on a catalogue of cannabis products like vapes, edibles, and smoking devices. Along with that, we’ve got deals on tons of cannabinoid compounds like the super popular delta-8 THC. Please keep in mind, *cannabinoid products are not everyone’s first choice. We support customers only buy products that they are fully comfortable with using.

The latest in Germany

When a government is in the midst of doing something, and it isn’t putting out direct information for its citizens, it means, it’s probably not going to, even if asked. I think we’re all aware that governments are good at giving government lines, wherein, questions are often ignored, in place of restating obvious lines. On one hand, populations seem so used to this treatment, that an ignored question and standard answer, actually make for coverable stories these days. On the other hand, perhaps if no formal statement is made, we shouldn’t expect an answer to the question anyway.

In early May, Germany’s Health Minister Karl Lauterbach confirmed to German newspaper Handelsblatt that he supports that the country legalize cannabis, saying “I’ve always been opposed to cannabis legalization, but I revised my position about a year ago.”

Earlier then that, on April 6th, Marco Buschmann, the Justice Minister announced that he was in the midst of strategizing a legalization in conjunction with the Ministry of Health, which would involve a consultation process. This process would included talks involving representation by federal, state, and local governments, along with other organizations. The conversation is set to start this summer, with a formal bill hoped for by late 2022.

Germany legalize

On the same day, via Twitter, Finance Minister Christian Lindner also confirmed – in a way – that the country was undertaking the legalization process, saying cannabis would be legal soon.

As you can see, none of this gives any real information about what to expect, or when. In fact, it sounds like a bunch of government ministers not wanting to say anything at all, or having nothing yet to say. So little has actually been confirmed, that it brings up the question of whether we’re sure Germany will go through with this. As of last fall, Germany made what sounds like an official decision to legalize, but how official is a decision with no legal backing?

Germany’s decision to legalize

Why do we keep looking to Germany’s government to give us more information on a legalization? Technically this decision was made back in October by the new government coalition ruling Germany, made up of three pro-legalization parties: Social Democrats (SPD), Green Party, and Free Democrats (FDP). By November 2021, it was said that a bill was in progress.

The decision was to create “the controlled sale of cannabis to adults for recreational purposes in licensed shops.” This would make cannabis accessible to adults 18 years and up. Whenever it comes out, a new Cannabis Control Law would regulate licensing for cultivation, and general rules of sale.

For years, Germany was ruled over by right-leaning coalitions, headed by Angela Merkel of the Christian Democrats. Cannabis reform was repeatedly blocked by these parties, even as Germany itself became more acclimated to the idea of it, with more of the population in agreement with its legalization. Perhaps this is one of the reasons that Angela Merkel stepped down, understanding that a new era is here.

In the last Bundestag elections in 2021, it was already known that Merkel, the chancellor since 2005, would step down. The resulting election saw the longstanding center-right Christian Democratic Union lose its upper hand in favor of the Social Democrats, a coalition partner to the CDU which is pro-weed, but which was constantly stifled by the CDU. This time around the SPD took the most seats, and left the Christian Democrats out of any coalition, instead forming one with two other pro-legalization parties. In fact, one of the first topics of business, was the agreed upon legalization of cannabis.

Germany elections

At that time, an anonymous representative explained to die Funke Mediengruppe publication, “We’re introducing the controlled distribution of cannabis to adults for consumption in licensed stores. This will control the quality, prevent the transfer of contaminated substances and guarantee the protection of minors. We will evaluate the law after four years for social impact.”

The new European trend of legalization

Usually in politics, we wait for bills to come out before coming to the understanding of a legal change. The reason for this, is that a lot of things are often said on a political stage, and not all (or even much) is actually relevant in the end. Tons of bills that get introduced, pushed hard, and lobbied for, die anyway, so even having a bill isn’t a direct lead-in to a new law. Statements without published laws behind them suffer under the weight of not having official backing, and in very few instances do we simply trust a statement when there is nothing to show for it.

However, the new trend in Europe is for countries to make statements, like Germany, about their decision to legalize cannabis. But with no approved legalization measure in sight. Does this mean the measures must go through? Quite the opposite. A statement of intention is not legally binding, and none of these statements must be honored.

Having said that, the statements themselves are essentially marketing lines, letting the world know the interests of these governments. It suffices to say that the reason these statements are trusted, is because the leadership of these countries have indicated a strong desire to reap the rewards of a cannabis market. So no, these are not official policies, but realistically, they almost certainly will go through.

Germany joins other countries in making promises to its citizens about an upcoming bill to legalize cannabis. The first to do it was Luxembourg. Back in September, 2021, Luxembourg became the first European country to make such a statement, while the bill it spoke of was merely a proposal. Under the proposal, Luxembourg would allow adult-use for 18+, and for private residents to grow up to four plants in a home. As stated, a lot of bills come up, and they don’t always go through, so even though Luxembourg pushed a story of being the first legalized country in Europe, it really is just pushing a standard bill.

Switzerland also got in big on making announcements for things that haven’t happened yet. In September 2021, it too declared the decision to legalize via the Social Security and Health Commission, which is a part of the Council of States, also known as the upper house of the Federal Assembly; Switzerland’s parliament. The council took a vote, with nine out of 11 members voting to change laws (not to directly legalize). The next move is for parliament to draft a bill, which means no laws are close to changing yet, and there is no guarantee that they will, or how they will.

legalize cannabis

On the other hand, Malta didn’t just make statements, but went all the way, actually becoming the first European country to pass a measure. It did so with Bill no. 241, on December 14th, 2021. The final vote for passage was 36 to 27. The new law permits cultivation and use, but does not set up a regulated sales market. Adults 18+ can have up to seven grams on their person, and up to 50 grams stored.

The country is looking to set up ‘associations’ in the place of a legal sales market, whereby non-profit organizations will grow and distribute plants and seeds. This sounds similar to Spain’s cannabis clubs, but whereas Spain’s clubs function off a legal loophole, Malta’s would function in an above-board fashion.


The world is moving in a very specific direction when it comes to cannabis legalization, even if it doesn’t always move fast. In fact, it’s moving so directly, that several countries are stating their future plans, without having the legislation to back them up. Luckily, since it’s a competitive market, and everyone wants money, Germany is expected to fulfill its intention to legalize, just like Switzerland and Luxembourg, as well.

Welcome everyone! We appreciate you stopping by, your preeminent internet location for updated and relevant independent coverage of the cannabis and psychedelics fields. Join us daily to stay abreast of all the moving pieces in these dynamic industries, and check out The THC Weekly Newsletter, to ensure you’re never late on getting a story.

Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.


Ticker: ‘Borat’ drops suit over pot billboard; Ringling Bros. announces comeback tour, no animals 




Actor Sacha Baron Cohen has dropped his lawsuit against a Massachusetts cannabis dispensary that used an image of his character Borat on a billboard without his permission.

A document filed in Boston federal court Tuesday said the two sides have agreed to dismiss the case brought last year by the “Borat” star.

The legal filing did not mention any settlement in the case. Emails seeking comment were sent Wednesday to lawyers for Baron Cohen and the dispensary, Somerset-based Solar Therapeutics Inc.

Read the rest of this story on

Source link

Continue Reading


Has the Cannabis Bubble Popped? – Cannabis News, Lifestyle




Has the cannabis bubble popped? Stocks are down, funds are drying up, and balance sheets are messy. Assets managed by cannabis funds are down by 45% in twelve months. They’ve reportedly lost $2.6 billion from $4.6 billion the previous year.

Morningstar, an investment research firm, provided the data.

What Happened?

Investors blame a popped cannabis bubble on several factors. First is the repeated failed attempts to pass federal legalization legislation in the United States. But funds focused on legal cannabis markets have also dropped. Data shows that 23 ETF funds have lost between 44.2% and 72% over 12 months.

Investors are seeing inflows dry up as well. In the first three months of 2022, they invested $95.6 million into cannabis funds, compared to $1.7 billion the year before.

However, last year’s activity may have had to do more with new listings on the London Stock Exchange. In the first five months of 2021, Oxford Cannabinoid Technologies, Kanabo Group, and MGC Pharmaceuticals doubled the size of the cannabis market.

Of course, like the rest of the sector, shares in these groups have dropped by 60% and 80%. Canadian LPs have faired a little better, but they’re still down over the same period. Aurora Cannabis is down 57%, Canopy Growth is down 74%, and Tilray is down 68%.

Putting Their Faith in Joe Biden 

cannabis bubble popped
Photo by: Gayatri Malhotra

Performance for cannabis funds doesn’t seem to follow any fundamentals, however. At the tail-end of 2020, cannabis funds picked up when media conglomerates declared Joe Biden the winner of the US presidential election. Funds rose further toward the inauguration when investors assumed the Democrats would make cannabis legalization a top priority. As well as passing legislation to make it easier for cannabis companies in the US to access the banking sector.

“Everybody is watching that one data point right now,” says Nawan Butt, manager of the Medical Cannabis and Wellness ETF. “Whether or not the Senate can pass the SAFE Act, which is expected to go through the Senate. If the SAFE Act gets passed, that will allow financial institutions to start helping the industry. This essentially means that industry participants will get better access to financing and better access to financial services. As well as, we’ll finally have investors in this space who aren’t afraid to be persecuted under federal laws for holding cannabis stocks.”

Blaming Consumers for A Popped Cannabis Bubble?

According to Morningstar figures, Global X is the worst performing cannabis ETF. Alec Lucas, research analyst at Global X, blamed consumers for pursuing “cheaper cannabis options sourced from illicit markets, which has contributed to slowing sales in markets such as Colorado, Illinois, Massachusetts, and Pennsylvania.” Adding, “Canadian companies have been unable to lift prices so as to remain competitive with illicit markets, leading to disappointing earnings.”

However, the truth may be more complex than consumers preferring legacy markets over pharmaceutical-grade cannabis.

Ethanol prices are up 35%, and this affects entrepreneurs using ethanol as a solvent for cannabis derivatives. Higher gas prices also strain margins for cannabis delivery services, including wholesale supply.

Easy Money At Fault for Popping the Cannabis Bubble?

The cannabis bubble may be popping because the era of easy money is coming to an end. Central banks worldwide are attempting to lift interest rates after over twenty years of keeping them near zero. Many economists suggest this manipulation of interest rates acts as an unnatural price control on the money supply. The result is a capital market that divorces itself from consumer demand.

In other words, market interest rates reflect consumer demand and the relative scarcity of capital. A central bank lowering interest rates below its market rate creates an illusion of more prosperity and, thus, the funds to realize long-term projects. However, as we’re discovering now, printing more money doesn’t create more resources. Banks and governments can blame supply chain disruptions on COVID or the Russians, but evidence points to monetary policy, namely easy money, being at fault.

An economy flush with easy money explains how Canada’s cannabis bubble grew to unprecedented heights. Large LPs are cash flow negative, and they have trouble competing with the legacy market and smaller craft producers. Despite their popularity in the financial world, the fundamentals are not there to support their business model. And with large LPs shutting down facilities and firing employees, it’s becoming more apparent every day that the cannabis bubble has popped.

Source link

Continue Reading

Aquis Growth Market

Publicly Traded: Which Psychedelics Companies Completed An IPO




The world of investment is a big place with a ton of offerings. In the last few years, a new genre of company has been added to the list of possible corporations to invest in. Yup, there are now a plethora of publicly traded psychedelics companies, and they’re all just getting started.

The world of publicly traded companies is always expanding, and now includes psychedelics companies. This was unheard of just a few years ago! We’re a news platform specializing in the psychedelics and cannabis industries, and the important stories within. Keep up with us by signing up for The Cannadelics Weekly Newsletter, and also be first in line for all product promotions, as they come out in the upcoming months.

What is an IPO?

There are different kinds of businesses. Some are small and operated by one person. Some are massive and span several continents, with thousands of employees. The latter, though it could be a private company, is most likely publicly traded.

A publicly traded company is one that sells its shares on a stock exchange, like the New York Stock Exchange, or the London Stock Exchange. The stocks reach the exchange via an initial public offering, or IPO, which is the opening sail of a company’s shares. Through the IPO, anyone in the general public can purchase a portion of the company, meaning that it’s not owned by a single person or group, but by whoever owns its shares. One of the benefits of doing this, is the ability to get capital together for expansion. One of the deficits, is losing control of a private company to a group of shareholders.

Public companies generally have a CEO and board of directors, as well as shareholders. Who holds the most power can vary between organizations. Decisions can be made by the board, which is generally made up of high level executives, or the shareholders by way of voting. All public companies are regulated by the Securities and Exchange Commission, under the eye of the PCAOB (Public Company Accounting Oversight Board).

IPO publicly traded companies

If a company does not go public, its control is retained by the smaller number of owners or investors that it has, and decisions are made at the behest of this smaller group. In some cases it’s a single person making these decisions. In some cases, a private company can be very large, like Cargill, the largest privately held company in the US, which boasts a staff of 113,000.

Anyone legally able with enough money can purchase shares of a publicly traded company on whatever exchange it exists on. For example, the biggest exchange for stocks in America is the New York Stock Exchange. But there are also other exchanges like the Nasdaq for buying and selling securities, and exchanges in other countries like Euronext, the EU’s biggest exchange.

One aspect of publicly traded companies is that they must report certain financial information to both the government and investors. This is not the same for private companies, which don’t have to release as much information, and can be more secretive about overall earnings. For some industries that hover mainly in the black or gray markets, there isn’t always much data released, and its through the reporting of public companies that we get any sales information at all. The cannabinoid market is a great example of this.

Since publicly traded companies are more closely regulated by federal agencies, they must be tax-paying companies, operating above-board. They might employ shady tactics, but they can’t be black market companies. As such, in order for publicly traded psychedelics companies to exist, they must not sell products or services that are federally illegal.

Publicly traded psychedelics companies

Psychedelics are making a huge comeback in light of study after study showing their benefits for both a myriad of psychological issues, as well as pain. In fact, psychedelic medications are now repeatedly showing up standard pharmaceutical remedies in both avenues, with the drug ketamine (and its legalized counterpart esketamine) taking the lead, highlighting the ability for better depression and pain management. This is especially important because of the ongoing and increasingly bad opioid epidemic which claims tens of thousands of lives a year.

Other compounds like psilocybin and MDMA are getting close to legalizations as well on a federal level. In fact, the FDA has helped structure trials with more than one company studying these compounds, to ensure trial results meet all regulation. The FDA also issued ‘Breakthrough Therapy’ status to three companies studying MDMA and psilocybin, in order to get their drugs to market faster.


One organization that received such treatment is MAPS – (Multidisciplinary Association of Psychedelic Studies) which is currently in Phase III trials into MDMA for PTSD. MAPS, however is not a corporation, but a non-profit group. Another organization that received this help from the FDA is COMPASS Pathways (CMPS) which is researching psilocybin for treatment resistant depression. COMPASS Pathways is a publicly traded psychedelics company on the Nasdaq and New York Stock Exchanges.

Other companies that join COMPASS on these two exchanges, include Field Trip Health, Inc. (TSE), one of the biggest operators of ketamine clinics; MindMed (MMED), a Swiss biotech company investigating how LSD and MDMA can be used in combination; and Atai Life Sciences (BMV), a company that acquires business in the psychedelics space, and which is one of the psychedelics company with the greatest market capital in 2022, topping $860 million. As of October 2021, there were at least nine publicly traded psychedelics companies on both the Nasdaq and NYSE.

OTC Exchange

However, some publicly traded psychedelics companies are traded elsewhere. In fact, the majority reside on the OTC Markets Group, which includes the OTCQX (highest tier), and OTCQB (mid-tier). Companies that show up here include Pharma Ther (PHRM) which is developing microneedle psilocybin skin patches for medical purposes. Mindset Pharma (MSET) which is working on psilocybin analogues, which are stronger than the standard compound. Delic Holdings Corp (DELC), another chain of ketamine clinics that just bought out Ketamine Wellness Centers Arizona LLC, with major expansion plans.

Then there’s Wesana Health Holdings (WESA), a developer of neurological health therapies, which announced in summer 2021 its acquisition of Psychedelitech, Inc. And Nova Mentis (NOVA), a company in the psilocybin skin patches space, working in conjunction with Mycrodose. All together, as of October 2021, there were at least 27 publicly traded psychedelics companies on the two top tiers of this exchange.

The lowest tier of the OTC exchange is called the Pink Open Market, and several more psychedelics companies reside here. One such company is Levitee Labs (LVT), which joined the Exchange in 2021, and is a producer of mushrooms and associated products. Another is Small Pharma (DMT), which is currently conducting the world’s first official DMT trials into depression along with Imperial College London. Another is Red Light Holland (TRIP), a Netherlands company that sells truffles in the legal market in the Netherlands. And Numinous (NUMI), a wellness company specializing in holistic treatments with psychedelic medicines. Altogether, as of late 2021, at least 14 companies were on this tier of the exchange.

Non-US exchanges

On the international stage, one of the biggest publicly traded psychedelics companies is Jazz Pharmaceuticals (JAZZ) out of Ireland, a Nasdaq company which announced its acquisition of GW Pharma in 2021. GW is a British pharmaceutical company and the maker of leading pharma medicines epidiolex and Sativex, the reason that the UK is one of the biggest cannabis exporters in the world.

public companies

Other companies not necessarily based around the US exchanges include Clarify Pharma (PSYC), a British company which is an investment platform that promotes psychedelic medicines, and which can be found on the Aquis Growth Market for equity and debt securities. Neon Mind (NEON) a Vancouver-based company working on psilocybin weight loss treatments, which resides on the Canadian Securities Exchange. And Graph Blockchain (GBLC), a blockchain company out of British Columbia, which recently acquired mushroom company Shroom Streets, making for a marriage between tech and treatment. This company can also be found on the Canadian Securities Exchange.

For those interested in private and public psychedelic investments, this list contains both companies in their respective spaces. For those interested in investing in private companies, and have the ability to do so, its best to contact the individual companies to speak with their management as shares are not open to the general public. For the right investors, private companies are great opportunities, though they won’t apply to most of the investing world.


If the idea is investment, interested investors should go through the publicly traded psychedelics companies to find the ones that best suit their investment needs. As a dynamic industry with many moving pieces, the landscape is sure to change soon enough, and those getting in on the action, would be wise to keep their eye on daily changes to promote safe and profitable investments. If you’re still unsure about investing in this marketplace, give it more time, and see if its any more appealing in a few months, or a year, from now.

Hello and welcome! Thanks for making it over to /, your top spot for fully-rounded independent news covering the expanding cannabis and psychedelics fields. Join us whenever possible to keep updated on these dynamic landscapes, and head over to The Cannadelics Weekly Newsletter, for your daily dose of industry news.

Source link

Continue Reading


Copyright © 2021 The Art of MaryJane Media